Histochemical Study of Vitiligo in Sohag University Hospital Patients

Not Applicable

Not yet recruiting

• Conditions: Vitiligo
• Interventions: Diagnostic Test: Light microscopic studies; Diagnostic Test: Immunohistochemical studies

• Registration Number: NCT05869942
• Lead Sponsor: Sohag University

Brief Summary

Vitiligo is a common acquired idiopathic disorder characterized by depigmentation of the skin, hair, and mucous membranes in the form of macules and patches due to selective melanocyte destruction . Incidence of Vitiligo is about 0.5% to 2% of the world's population, and its incidence continues to increase. Vitiligo can appear at any age group especially in the second and third decades of life. About one-third of vitiligo patients are children under ten years old Vitiligo can be classified into non-segmental, segmental, mixed and unclassifiable/undetermined types. Vitiligo has a negative impact on patient's quality of life by decreasing their self-confidence and causing significant psychological distress.

Detailed Description

The pathogenesis of vitiligo is still unclear but some theories can explain it such as oxidative stress, autoimmunity, autocytotoxicity, genetic factors, neural and melanocytorrhagy . Loss of pigment which occur in vitiligo may be due to two main causes: absence of melanocytes and/or the inability of melanocytes to produce and store melanin in melanosomes in the process of melanogenesis.

High mobility group box protein B1 (HMGB1) normally presents in the nucleus to maintain genomic stabilization and regulate gene transcription. but, HMGB1 can be released outside the cell due to exposure to stressful factors such as oxidative stress and function as a damage-associated molecular pattern (DAMP) protein leading to strong proinflammatory effects. Recent data showed that HMGB1 is overexpressed in both blood and lesional specimens from vitiligo patients. Moreover, oxidative stress triggers the release of HMGB1 from keratinocytes and melanocytes, indicating that HMGB1 may participate and play a crucial role in the pathological process of vitiligo.

HMGB1 Directly induces Melanocyte apoptosis through stimulation with reactive oxidative stress (ROS) or ultraviolet B (UVB) in vitro which significantly increases the release of HMGB1 from keratinocytes, which inhibits the expression of melanogenesis-related molecules such as microphthalmia- associated transcription factor (MITF), tyrosinase-related proteins and the gp100 protein in a paracrine manner and finally activate caspase-3 to trigger melanocyte apoptosis

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2023-05
• Study First Submitted: 2023-05-10
• Study First Submitted QC: 2023-05-19
• Last Update Submitted: 2023-05-19
• Study First Posted: 2023-05-22
• Last Update Posted: 2023-05-22
• Study Start: 2023-06-15
• Primary Completion: 2024-06-15
• Study Completion: 2024-08-15

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• The study will include patients with vitiligo aged 18-50 years old.

Read More

Exclusion Criteria

• Pregnancy
• Lactation
• Patient on immunosuppressive treatment for vitiligo over the last month
• Skin diseases, other than vitiligo.
• Systemic diseases particulary endocrine disorders and autoimmune connective tissue diseases.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
group B(Control group)	Light microscopic studies	Normal control group not diseased
group B(Control group)	Immunohistochemical studies	Normal control group not diseased
groupA (Diseased group)	Light microscopic studies	patients with Vitiligo
groupA (Diseased group)	Immunohistochemical studies	patients with Vitiligo

Primary Outcome Measures

Name	Time	Method
Assessment of tissue expression of active caspase 3 in patients with vitiligo compared to normal	12 months	active caspase 3 antibodie assessment by Skin biopsy from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin.
Assessment of tissue expression of HMGB1 in patients with vitiligo compared to normal control.	12 months	Monoclonal HMGB1 antibodie assessment by Skin biopsy from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin.

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt